Tarek Bekfani1, Mohamed Bekhite Elsaied2, Steffen Derlien3, Jenny Nisser3, Martin Westermann4, Sandor Nietzsche4, Ali Hamadanchi2, Elisabeth Fröb2, Julian Westphal2, Daniela Haase2, Tom Kretzschmar2, Peter Schlattmann5, Ulrich C Smolenski3, Michael Lichtenauer6, Bernhard Wernly6, Peter Jirak6, Gabriele Lehmann7,5, Sven Möbius-Winkler2, P Christian Schulze2. 1. Division of Cardiology, Angiology, Pneumology, and Intensive Medical Care, Department of Internal Medicine, University Hospital Magdeburg, Otto-von Guericke University, Magdeburg, Germany (T.B.). 2. Division of Cardiology, Pneumology, and Intensive Medical Care, Department of Internal Medicine I (M.B.E., A.H., E.F., J.W., D.H., T.K., S.M.-W., P.C.S.), Friedrich-Schiller-University, Germany. 3. University Hospital Jena, Institute of Physiotherapy (S.D., J.N., U.C.S.), Friedrich-Schiller-University, Germany. 4. Center of Electron Microscopy (M.W., S.N.), Friedrich-Schiller-University, Germany. 5. Institute for Medical Statistics, Computer Science and Data Science (IMSID), Jena University Hospital, Germany (P.S., G.L.). 6. Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Austria (M.L., P.W., P.J.). 7. Division of Endocrinology, Nephrology and Rheumatology, Department of Internal Medicine III (G.L.), Friedrich-Schiller-University, Germany.
Abstract
BACKGROUND: Reduced exercise capacity in patients with heart failure (HF) could be partially explained by skeletal muscle dysfunction. We compared skeletal muscle function, structure, and metabolism among clinically stable outpatients with HF with preserved ejection fraction, HF with reduced ejection fraction, and healthy controls (HC). Furthermore, the molecular, metabolic, and clinical profile of patients with reduced muscle endurance was described. METHODS: Fifty-five participants were recruited prospectively at the University Hospital Jena (17 HF with preserved ejection fraction, 18 HF with reduced ejection fraction, and 20 HC). All participants underwent echocardiography, cardiopulmonary exercise testing, 6-minute walking test, isokinetic muscle function, and skeletal muscle biopsies. Expression levels of fatty acid oxidation, glucose metabolism, atrophy genes, and proteins as well as inflammatory biomarkers were assessed. Mitochondria were evaluated using electron microscopy. RESULTS: Patients with HF with preserved ejection fraction showed compared with HF with reduced ejection fraction and HC reduced muscle strength (eccentric extension: 13.3±5.0 versus 18.0±5.9 versus 17.9±5.1 Nm/kg, P=0.04), elevated levels of MSTN-2 (myostatin-2), FBXO-32 (F-box only protein 32 [Atrogin1]) gene and protein, and smaller mitochondrial size (P<0.05). Mitochondrial function and fatty acid and glucose metabolism were impaired in HF-patients compared with HC (P<0.05). In a multiple regression analysis, GDF-15 (growth and differentiation factor 15), CPT1B (carnitine palmitoyltransferase IB)-protein and oral anticoagulation were independent factors for predicting reduced muscle endurance after adjusting for age (log10 GDF-15 [pg/mL] [B, -54.3 (95% CI, -106 to -2.00), P=0.043], log10 CPT1B per fold increase [B, 49.3 (95% CI, 1.90-96.77), P=0.042]; oral anticoagulation present [B, 44.8 (95% CI, 27.90-61.78), P<0.001]). CONCLUSIONS: Patients with HF with preserved ejection fraction have worse muscle function and predominant muscle atrophy compared with those with HF with reduced ejection fraction and HC. Inflammatory biomarkers, fatty acid oxidation, and oral anticoagulation were independent factors for predicting reduced muscle endurance.
BACKGROUND: Reduced exercise capacity in patients with heart failure (HF) could be partially explained by skeletal muscle dysfunction. We compared skeletal muscle function, structure, and metabolism among clinically stable outpatients with HF with preserved ejection fraction, HF with reduced ejection fraction, and healthy controls (HC). Furthermore, the molecular, metabolic, and clinical profile of patients with reduced muscle endurance was described. METHODS: Fifty-five participants were recruited prospectively at the University Hospital Jena (17 HF with preserved ejection fraction, 18 HF with reduced ejection fraction, and 20 HC). All participants underwent echocardiography, cardiopulmonary exercise testing, 6-minute walking test, isokinetic muscle function, and skeletal muscle biopsies. Expression levels of fatty acid oxidation, glucose metabolism, atrophy genes, and proteins as well as inflammatory biomarkers were assessed. Mitochondria were evaluated using electron microscopy. RESULTS:Patients with HF with preserved ejection fraction showed compared with HF with reduced ejection fraction and HC reduced muscle strength (eccentric extension: 13.3±5.0 versus 18.0±5.9 versus 17.9±5.1 Nm/kg, P=0.04), elevated levels of MSTN-2 (myostatin-2), FBXO-32 (F-box only protein 32 [Atrogin1]) gene and protein, and smaller mitochondrial size (P<0.05). Mitochondrial function and fatty acid and glucose metabolism were impaired in HF-patients compared with HC (P<0.05). In a multiple regression analysis, GDF-15 (growth and differentiation factor 15), CPT1B (carnitine palmitoyltransferase IB)-protein and oral anticoagulation were independent factors for predicting reduced muscle endurance after adjusting for age (log10 GDF-15 [pg/mL] [B, -54.3 (95% CI, -106 to -2.00), P=0.043], log10 CPT1B per fold increase [B, 49.3 (95% CI, 1.90-96.77), P=0.042]; oral anticoagulation present [B, 44.8 (95% CI, 27.90-61.78), P<0.001]). CONCLUSIONS:Patients with HF with preserved ejection fraction have worse muscle function and predominant muscle atrophy compared with those with HF with reduced ejection fraction and HC. Inflammatory biomarkers, fatty acid oxidation, and oral anticoagulation were independent factors for predicting reduced muscle endurance.
Authors: Rachel C Kelley; Lauren Betancourt; Andrea M Noriega; Suzanne C Brinson; Nuria Curbelo-Bermudez; Dongwoo Hahn; Ravi A Kumar; Eliza Balazic; Derek R Muscato; Terence E Ryan; Robbert J van der Pijl; Shengyi Shen; Coen A C Ottenheijm; Leonardo F Ferreira Journal: J Appl Physiol (1985) Date: 2021-11-18
Authors: Tarek Bekfani; Mohamed Bekhite; Sophie Neugebauer; Steffen Derlien; Ali Hamadanchi; Jenny Nisser; Marion S Hilse; Daniela Haase; Tom Kretzschmar; Mei-Fang Wu; Michael Lichtenauer; Michael Kiehntopf; Stephan von Haehling; Peter Schlattmann; Gabriele Lehmann; Marcus Franz; Sven Möbius-Winkler; Christian Schulze Journal: Cells Date: 2022-05-18 Impact factor: 7.666
Authors: Iván José Fuentes-Abolafio; Adrian Escriche-Escuder; María Rosa Bernal-López; Ricardo Gómez-Huelgas; Michele Ricci; Manuel Trinidad-Fernández; Cristina Roldán-Jiménez; José María Arjona-Caballero; Antonio Ignacio Cuesta-Vargas; Luis Miguel Pérez-Belmonte Journal: J Clin Med Date: 2022-05-10 Impact factor: 4.964
Authors: Payman Zamani; Elizabeth A Proto; Neil Wilson; Hossein Fazelinia; Hua Ding; Lynn A Spruce; Antonio Davila; Thomas C Hanff; Jeremy A Mazurek; Stuart B Prenner; Benoit Desjardins; Kenneth B Margulies; Daniel P Kelly; Zoltan Arany; Paschalis-Thomas Doulias; John W Elrod; Mitchell E Allen; Shana E McCormack; Gayatri Maria Schur; Kevin D'Aquilla; Dushyant Kumar; Deepa Thakuri; Karthik Prabhakaran; Michael C Langham; David C Poole; Steven H Seeholzer; Ravinder Reddy; Harry Ischiropoulos; Julio A Chirinos Journal: ESC Heart Fail Date: 2021-05-15
Authors: Gijs van Woerden; Dirk J van Veldhuisen; Olivier C Manintveld; Vanessa P M van Empel; Tineke P Willems; Rudolf A de Boer; Michiel Rienstra; B Daan Westenbrink; Thomas M Gorter Journal: Circ Heart Fail Date: 2021-12-22 Impact factor: 8.790
Authors: Stefano Gobbo; Francesco Favro; Valentina Bullo; Lucia Cugusi; Andrea Di Blasio; Alessandro Bortoletto; Danilo Sales Bocalini; Andrea Gasperetti; Andrea Ermolao; Marco Bergamin Journal: Front Physiol Date: 2022-08-08 Impact factor: 4.755